Allarity Reaches Final Settlement With SEC To Resolve Investigation - Quick Facts

(RTTNews) - Allarity Therapeutics (ALLR) has reached a final settlement with the SEC relating to the previously disclosed investigation regarding the companys past disclosures concerning interactions with the FDA regarding NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. The final settlement confirmed the settlement in principle announced by the company on January 30, 2025. The settlement resolves the SEC's investigation.

Thomas Jensen, CEO of Allarity Therapeutics, said: "Coming shortly after the dismissal of the securities class action lawsuit in February, this marks the conclusion of all outstanding legal matters for Allarity. With these issues behind us, we can now fully focus on our mission of advancing our novel PARP/Wnt inhibitor through the clinical development plans we have already announced."

For More Such Health News, visit rttnews.com.